Özet
Non-pharmacological, pharmacological and invasive treatment methods are used for the treatment of children with voiding dysfunction and non-invasive and invasive methods are used in the diagnosis and follow-up of these patients. At the same time, the search for new diagnostic, treatment and follow-up methods continues. Percutaneous posterior tibial nerve stimulation (PPTNS) is one of the recommended treatment modalities in these patients. There are few studies in the literature to show the role of urine biomarkers in diagnosis and follow-up. Few studies have shown the potential benefits of NGF (nerve growth factor), TGF-beta 1 (transforming growth factor-beta 1), TIMP-2 (tissue inhibitor of metalloproteinases 2). Thus a prospective randomized, controlled study was planned to demonstrate the efficacy of transcutaneous posterior tibial nerve stimulation (TPTNS), which is a less invasive and therefore more tolerable method and to assess the role of urinary biomarkers (NGF, TGF-beta 1, TIMP-2) in the diagnosis and follow-up of children with voiding dysfunction. For this purpose, children between 6-15 years old who stopped treatment due to side effects and who were resistant to medical treatment between 01.2018-09.2018 were included to our study. Patients were divided into two goups; test (N=20) and sham (N=10) group by closed envelope method. TPTNS therapy was applied to the test group for 12 weeks, in 30 minute sessions once a week by stimulation given at certain dose intervals. The same procedure was applied to the sham group without any stimulation. Urine biomarkers, dysfunctional voiding and incontinence scoring system (DVISS), voiding diary, urodynamic or uroflowmetry tests were applied to both groups before and after treatment. In addition, to 14 healthy children without urinary complaints DVISS scores and urine biomarkers were evaluated for control group. In the test group, the frequency of urgency after treatment (p < 0.001), daytime incontinence episodes (p < 0.006), general DVISS scores (p < 0.001), daytime DVISS scores (p < 0.001) and quality of life score (p = 0.019) were significantly decreased. There were also significant decreases in general DVISS scores (p = 0.007), daytime DVISS scores (p = 0.005) and quality of life scores (p = 0.040) in the sham group. There was no difference between NGF (p = 0.199), TGF-beta 1 (p = 0.480), and TIMP-2 (p = 0.940) levels of patient and healthy volunteers group before treatment. Neither the NGF, TGF-beta 1, TIMP-2 levels in the test group (p = 0.250; 0.850; 0.460, respectively) nor the NGF, TGF-beta 1, TIMP-2 levels in the sham group (p = 0.580; 0.580; 0.650, respectively) changed significantly with the treatment. In our study, it was observed that TPTNS treatment provides significant improvement in some parameters of pediatric patients with voiding dysfunction. These findings support that TPTNS has a role in the treatment of pediatric patient group who does not respond to standard medical treatment. The benefit of TPTNS to the aforementioned patient group is observed especially in daytime symptoms. Further studies with greater number of patients are needed on this issue. According to our findings, urine biomarkers (NGF, TGF-beta1, TIMP-2) are not useful for diagnosis and follow-up of these patients.
Künye
1. Vaz GT, Vasconcelos MM, Oliveira EA, Ferreira AL, Magalhaes PG, Silva FM, et al. Prevalence of lower urinary tract symptoms in school-age children. Pediatric nephrology (Berlin, Germany). 2012;27(4):597-603.
2. Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children's Continence Society. Neurourol Urodyn. 2016;35(4):471-81.
3. Chen JJ, Pugach J, West D, Naseer S, Steinhardt GF. Infant vesicoureteral reflux: a comparison between patients presenting with a prenatal diagnosis and those presenting with a urinary tract infection. Urology. 2003;61(2):442-6; discussion 6-7.
4. Fernandez N, Chua ME, Ming JM, Silangcruz JM, Zu'bi F, Dos Santos J, et al. Neurostimulation Therapy for Non-neurogenic Overactive Bladder in Children: A Meta-analysis. Urology. 2017;110:201-7.
5. Patidar N, Mittal V, Kumar M, Sureka SK, Arora S, Ansari MS. Transcutaneous posterior tibial nerve stimulation in pediatric overactive bladder: A preliminary report. Journal of pediatric urology. 2015;11(6):351.e1-6.
6. Boudaoud N, Binet A, Line A, Chaouadi D, Jolly C, Fiquet CF, et al. Management of refractory overactive bladder in children by transcutaneous posterior tibial nerve stimulation: A controlled study. Journal of pediatric urology. 2015;11(3):138.e1-10.
7. Ergin G, Kibar Y, Ebiloglu T, Irkilata HC, Kopru B, Kaya E, et al. The role of urinary nerve growth factor for the diagnosis and assessment of the biofeedback success in children with dysfunctional voiding. Journal of pediatric urology. 2016;12(2):118.e1-6.
8. Sekerci CA, Isbilen B, Isman F, Akbal C, Simsek F, Tarcan T. Urinary NGF, TGF-beta1, TIMP-2 and bladder wall thickness predict neurourological findings in children with myelodysplasia. The Journal of urology. 2014;191(1):199-205.
9. de Groat WC, Griffiths D, Yoshimura N. Neural control of the lower urinary tract. Comprehensive Physiology. 2015;5(1):327-96.
10. Franco I. Overactive bladder in children. Part 1: Pathophysiology. The Journal of urology. 2007;178(3 Pt 1):761-8; discussion 8.
11. Yeung CK, Godley ML, Dhillon HK, Duffy PG, Ransley PG. Urodynamic patterns in infants with normal lower urinary tracts or primary vesico-ureteric reflux. British journal of urology. 1998;81(3):461-7.
12. Bower WF, Moore KH, Adams RD, Shepherd RB. Frequency-volume chart data from incontinent children. British journal of urology. 1997;80(4):658-62.
13. Holmdahl G, Hanson E, Hanson M, Hellstrom AL, Hjalmas K, Sillen U. Four-hour voiding observation in healthy infants. The Journal of urology. 1996;156(5):1809-12.
14. Mellon MW, Whiteside SP, Friedrich WN. The relevance of fecal soiling as an indicator of child sexual abuse: a preliminary analysis. Journal of developmental and behavioral pediatrics : JDBP. 2006;27(1):25-32.
15. Mattsson SH. Voiding frequency, volumes and intervals in healthy schoolchildren. Scandinavian journal of urology and nephrology. 1994;28(1):1-11.
16. Szabo L, Fegyverneki S. Maximum and average urine flow rates in normal children--the Miskolc nomograms. British journal of urology. 1995;76(1):16-20.
17. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49.
18. Dogan HS, Akpinar B, Gurocak S, Akata D, Bakkaloglu M, Tekgul S. Non-invasive evaluation of voiding function in asymptomatic primary school children. Pediatric nephrology (Berlin, Germany). 2008;23(7):1115-22.
19. Akbal C, Genc Y, Burgu B, Ozden E, Tekgul S. Dysfunctional voiding and incontinence scoring system: quantitative evaluation of incontinence symptoms in pediatric population. The Journal of urology. 2005;173(3):969-73.
20. Altan M, Citamak B, Bozaci AC, Mammadov E, Dogan HS, Tekgul S. Is There Any Difference Between Questionnaires on Pediatric Lower Urinary Tract Dysfunction? Urology. 2017;103:204-8.
21. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology. 2006;130(5):1527-37.
22. Burgers RE, Mugie SM, Chase J, Cooper CS, von Gontard A, Rittig CS, et al. Management of functional constipation in children with lower urinary tract symptoms: report from the Standardization Committee of the International Children's Continence Society. The Journal of urology. 2013;190(1):29-36.
23. Martinez-Lage JF, Niguez BF, Perez-Espejo MA, Almagro MJ, Maeztu C. Midline cutaneous lumbosacral lesions: not always a sign of occult spinal dysraphism. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2006;22(6):623-7.
24. de Wall LL, Heesakkers JP. Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome. Research and reports in urology. 2017;9:145-57.
25. Hoebeke P, Renson C, Petillon L, Vande Walle J, De Paepe H. Percutaneous electrical nerve stimulation in children with therapy resistant nonneuropathic bladder sphincter dysfunction: a pilot study. The Journal of urology. 2002;168(6):2605-7; discussion 7-8.
26. Chuang Y-C, Tyagi V, Liu R-T, Chancellor MB, Tyagi P. Urine and Serum C-Reactive Protein Levels as Potential Biomarkers of Lower Urinary Tract Symptoms. Urological Science. 2010;21(3):132-6.
27. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. The Journal of urology. 2006;175(5):1773-6; discussion 6.
28. Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU international. 2009;103(12):1668-72.
29. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to evolu botulinum toxin-A injection. European urology. 2009;56(4):700-6.
30. Oddiah D, Anand P, McMahon SB, Rattray M. Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder. Neuroreport. 1998;9(7):1455-8.
31. Bhide AA, Cartwright R, Khullar V, Digesu GA. Biomarkers in overactive bladder. International urogynecology journal. 2013;24(7):1065-72.
32. Okragly AJ, Niles AL, Saban R, Schmidt D, Hoffman RL, Warner TF, et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. The Journal of urology. 1999;161(2):438-41; discussion 41-2.
33. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007;70(3):463-8.
34. Seki S, Sasaki K, Fraser MO, Igawa Y, Nishizawa O, Chancellor MB, et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. The Journal of urology. 2002;168(5):2269-74.
35. Top T, Sekerci CA, Isbilen-Basok B, Tanidir Y, Tinay I, Isman FK, et al. The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia. Neurourol Urodyn. 2017;36(7):1896-902.
36. Rittig S, Kamperis K, Siggaard C, Hagstroem S, Djurhuus JC. Age related nocturnal urine volume and maximum voided volume in healthy children: reappraisal of International Children's Continence Society definitions. The Journal of urology. 2010;183(4):1561-7.
37. Yaðmur Ý. Normal voiding curve. Journal of the Turkish Association of Pediatric Surgeons and The Society for Pediatric Urology in Turkey. 2016;30(100):571-4.
38. Yang SS, Chang SJ. The effects of bladder over distention on voiding function in kindergarteners. The Journal of urology. 2008;180(5):2177-82; discussion 82.
39. Beksac AT, Koni A, Bozaci AC, Dogan HS, Tekgul S. Postvoidal residual urine is the most significant non-invasive diagnostic test to predict the treatment outcome in children with non-neurogenic lower urinary tract dysfunction. Journal of pediatric urology. 2016;12(4):215.e1-8.
40. Gutierrez Segura C. Urine flow in childhood: a study of flow chart parameters based on 1,361 uroflowmetry tests. The Journal of urology. 1997;157(4):1426-8.
41. Chang SJ, Yang SS. Variability, related factors and normal reference value of post-void residual urine in healthy kindergarteners. The Journal of urology. 2009;182(4 Suppl):1933-8.
42. Barrett DM, Wein AJ. Flow evaluation and simultaneous external sphincter electromyography in clinical urodynamics. The Journal of urology. 1981;125(4):538-41.
43. Wenske S, Combs AJ, Van Batavia JP, Glassberg KI. Can staccato and interrupted/fractionated uroflow patterns alone correctly identify the underlying lower urinary tract condition? The Journal of urology. 2012;187(6):2188-93.
44. Muller L, Bergstrom T, Hellstrom M, Svensson E, Jacobsson B. Standardized ultrasound method for assessing detrusor muscle thickness in children. The Journal of urology. 2000;164(1):134-8.
45. Saxton HM, Borzyskowski M, Robinson LB. Nonobstructive posterior urethral widening (spinning top urethra) in boys with bladder instability. Radiology. 1992;182(1):81-5.
46. Chin-Peuckert L, Komlos M, Rennick JE, Jednak R, Capolicchio JP, Salle JL. What is the variability between 2 consecutive cystometries in the same child? The Journal of urology. 2003;170(4 Pt 2):1614-7.
47. Park JM, Bloom DA, McGuire EJ. The guarding reflex revisited. British journal of urology. 1997;80(6):940-5.
48. Bower WF, Moore KH, Shepherd RB, Adams RD. The epidemiology of childhood enuresis in Australia. British journal of urology. 1996;78(4):602-6.
49. Tarhan H, Cakmak O, Akarken I, Ekin RG, Un S, Uzelli D, et al. Toilet training age and influencing factors: a multicenter study. The Turkish journal of pediatrics. 2015;57(2):172-6.
50. Soygur T, Arikan N, Tokatli Z, Karaboga R. The role of video-urodynamic studies in managing non-neurogenic voiding dysfunction in children. BJU international. 2004;93(6):841-3.
51. Franco I. Pediatric overactive bladder syndrome: pathophysiology and management. Paediatric drugs. 2007;9(6):379-90.
52. von Gontard A, Equit M. Comorbidity of ADHD and incontinence in children. European child & adolescent psychiatry. 2015;24(2):127-40.
53. Koff SA, Lapides J, Piazza DH. Association of urinary tract infection and reflux with uninhibited bladder contractions and voluntary sphincteric obstruction. The Journal of urology. 1979;122(3):373-6.
54. Loening-Baucke V. Urinary incontinence and urinary tract infection and their resolution with treatment of chronic constipation of childhood. Pediatrics. 1997;100(2 Pt 1):228-32.
55. Ural Z, Ulman I, Avanoglu A. Bladder dynamics and vesicoureteral reflux: factors associated with idiopathic lower urinary tract dysfunction in children. The Journal of urology. 2008;179(4):1564-7.
56. Bower WF, Yip SK, Yeung CK. Dysfunctional elimination symptoms in childhood and adulthood. The Journal of urology. 2005;174(4 Pt 2):1623-7; discussion 7-8.
57. Upadhyay J, Bolduc S, Bagli D, A McLorie G, E Khoury A, Farhat W. Use of the Dysfunctional Voiding Symptom Score to Predict Resolution of Vesicoureteral Reflux in Children With Voiding Dysfunction2003. 1842-6; discussion 6; author reply 6 p.
58. Hellerstein S, Linebarger JS. Voiding dysfunction in pediatric patients. Clinical pediatrics. 2003;42(1):43-9.
59. Chandra M, Saharia R, Shi Q, Hill V. Giggle incontinence in children: a manifestation of detrusor instability. The Journal of urology. 2002;168(5):2184-7; discussion 7.
60. Chase JW, Homsy Y, Siggaard C, Sit F, Bower WF. Functional constipation in children. The Journal of urology. 2004;171(6 Pt 2):2641-3.
61. Sampaio C, Sousa AS, Fraga LG, Veiga ML, Bastos Netto JM, Barroso U, Jr. Constipation and Lower Urinary Tract Dysfunction in Children and Adolescents: A Population-Based Study. Frontiers in pediatrics. 2016;4:101.
62. Chen JJ, Mao W, Homayoon K, Steinhardt GF. A multivariate analysis of dysfunctional elimination syndrome, and its relationships with gender, urinary tract infection and vesicoureteral reflux in children. The Journal of urology. 2004;171(5):1907-10.
63. Erickson BA, Austin JC, Cooper CS, Boyt MA. Polyethylene glycol 3350 for constipation in children with dysfunctional elimination. The Journal of urology. 2003;170(4 Pt 2):1518-20.
64. Hagstroem S, Rittig S, Kamperis K, Djurhuus JC. Timer watch assisted urotherapy in children: a randomized controlled trial. The Journal of urology. 2010;184(4):1482-8.
65. Chase J, Austin P, Hoebeke P, McKenna P. The management of dysfunctional voiding in children: a report from the Standardisation Committee of the International Children's Continence Society. The Journal of urology. 2010;183(4):1296-302.
66. Pohl HG, Bauer SB, Borer JG, Diamond DA, Kelly MD, Grant R, et al. The outcome of voiding dysfunction managed with clean intermittent catheterization in neurologically and anatomically normal children. BJU international. 2002;89(9):923-7.
67. Klingler HC, Pycha A, Schmidbauer J, Marberger M. Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology. 2000;56(5):766-71.
68. Veiga ML, Queiroz AP, Carvalho MC, Braga AA, Sousa AS, Barroso U, Jr. Parasacral transcutaneous electrical stimulation for overactive bladder in children: An assessment per session. Journal of pediatric urology. 2016;12(5):293.e1-.e5.
69. Roth TJ, Vandersteen DR, Hollatz P, Inman BA, Reinberg YE. Sacral neuromodulation for the dysfunctional elimination syndrome: a single center experience with 20 children. The Journal of urology. 2008;180(1):306-11; discussion 11.
70. Halliday S, Meadow SR, Berg I. Successful management of daytime enuresis using alarm procedures: a randomly controlled trial. Archives of disease in childhood. 1987;62(2):132-7.
71. Nijman RJ. Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children. Urology. 2004;63(3 Suppl 1):45-50.
72. Hjalmas K, Passerini-Glazel G, Chiozza ML. Functional daytime incontinence: pharmacological treatment. Scandinavian journal of urology and nephrology Supplementum. 1992;141:108-14; discussion 15-6.
73. Youdim K, Kogan BA. Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology. 2002;59(3):428-32.
74. Kaplinsky R, Greenfield S, Wan J, Fera M. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. The Journal of urology. 1996;156(2 Pt 2):753-6.
75. Marschall-Kehrel D, Feustel C, Persson de Geeter C, Stehr M, Radmayr C, Sillen U, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. European urology. 2009;55(3):729-36.
76. Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. The Journal of urology. 2003;170(5):1908-12.
77. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. European urology. 2009;55(1):100-19.
78. Hoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen P, et al. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. The Journal of urology. 2006;176(1):328-30; discussion 30-1.
79. Lahdes-Vasama TT, Anttila A, Wahl E, Taskinen S. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study. Scandinavian journal of urology and nephrology. 2011;45(6):397-400.
80. Leon P, Jolly C, Binet A, Fiquet C, Vilette C, Lefebvre F, et al. Botulinum toxin injections in the management of non-neurogenic overactive bladders in children. Journal of pediatric surgery. 2014;49(9):1424-8.
81. De Gennaro M, Capitanucci ML, Mastracci P, Silveri M, Gatti C, Mosiello G. Percutaneous tibial nerve neuromodulation is well tolerated in children and effective for treating refractory vesical dysfunction. The Journal of urology. 2004;171(5):1911-3.
82. Capitanucci ML, Camanni D, Demelas F, Mosiello G, Zaccara A, De Gennaro M. Long-term efficacy of percutaneous tibial nerve stimulation for different types of lower urinary tract dysfunction in children. The Journal of urology. 2009;182(4 Suppl):2056-61.
83. Hoebeke P, Van Laecke E, Van Camp C, Raes A, Van De Walle J. One thousand video-urodynamic studies in children with non-neurogenic bladder sphincter dysfunction. BJU international. 2001;87(6):575-80.
84. Fernandez-Ibieta M, Ayuso-Gonzalez L. Dysfunctional Voiding in Pediatrics: A Review of Pathophysiology and Current Treatment Modalities. Current pediatric reviews. 2016;12(4):292-300.
85. Lebl A, Fagundes SN, Koch VH. Clinical course of a cohort of children with non-neurogenic daytime urinary incontinence symptoms followed at a tertiary center. Jornal de pediatria. 2016;92(2):129-35.
86. Tafuro L, Montaldo P, Iervolino LR, Cioce F, del Gado R. Ultrasonographic bladder measurements can replace urodynamic study for the diagnosis of non-monosymptomatic nocturnal enuresis. BJU international. 2010;105(1):108-11.
87. Farhat W, Bagli DJ, Capolicchio G, O'Reilly S, Merguerian PA, Khoury A, et al. The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. The Journal of urology. 2000;164(3 Pt 2):1011-5.
88. Lopes I, Veiga ML, Braga AA, Brasil CA, Hoffmann A, Barroso U, Jr. A two-day bladder diary for children: Is it enough? Journal of pediatric urology. 2015;11(6):348.e1-4.
89. Lackgren G, Hjalmas K, van Gool J, von Gontard A, de Gennaro M, Lottmann H, et al. Nocturnal enuresis: a suggestion for a European treatment strategy. Acta paediatrica (Oslo, Norway : 1992). 1999;88(6):679-90.
90. Neveus T, Lackgren G, Tuvemo T, Hetta J, Hjalmas K, Stenberg A. Enuresis--background and treatment. Scandinavian journal of urology and nephrology Supplementum. 2000(206):1-44.
91. Yaðmur Ý. Urodynamic equipment. Journal of the Turkish Association of Pediatric Surgeons and The Society for Pediatric Urology in Turkey. 2016;30(100):559-64.
92. Shei-Dei Yang S, Chiang I-N, Chang S-J. Interpretation of uroflowmetry and post-void residual urine in children: fundamental approach to pediatric non-neurogenic voiding dysfunction.
93. Hjalmas K. Urodynamics in normal infants and children. Scandinavian journal of urology and nephrology Supplementum. 1988;114:20-7.
94. Norgaard JP, van Gool JD, Hjalmas K, Djurhuus JC, Hellstrom AL. Standardization and definitions in lower urinary tract dysfunction in children. International Children's Continence Society. British journal of urology. 1998;81 Suppl 3:1-16.
95. Neveus T, von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. The Journal of urology. 2006;176(1):314-24.
96. Jansson UB, Hanson M, Sillen U, Hellstrom AL. Voiding pattern and acquisition of bladder control from birth to age 6 years--a longitudinal study. The Journal of urology. 2005;174(1):289-93.
97. de Wall LL, Heesakkers JP. Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome. Research and reports in urology. 2017;9:145-57.
98. Franco I, Horowitz M, Grady R, Adams RC, de Jong TP, Lindert K, et al. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. The Journal of urology. 2005;173(1):221-5.
99. Alloussi S, Murtz G, Braun R, Gerhardt U, Heinrich M, Hellmis E, et al. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. BJU international. 2010;106(4):550-6.
100. D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. Journal of managed care pharmacy : JMCP. 2008;14(3):291-301.
101. Appell RA. The newer antimuscarinic drugs: bladder control with less dry mouth. Cleveland Clinic journal of medicine. 2002;69(10):761, 5-6, 8-9.
102. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206-16.
